多基原中药质量评价研究进展  

Research progress on quality evaluation of multi-source traditional Chinese medicine

作　　者：孙雪倩 杨彬[1] 李遇伯[1] SUN Xueqian;YANG Bin;LI Yubo(School of Chinese Materia Medica,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China)

机构地区：[1]天津中医药大学中药学院,天津301617

出　　处：《中草药》2024年第12期4214-4224,共11页Chinese Traditional and Herbal Drugs

基　　金：国家自然科学基金资助项目(82004225)。

摘　　要：多基原中药质量评价是保障其临床用药有效性和安全性的重要环节。目前,多基原中药质量评价仍存在基原鉴定方法专属性较差,多基原中药品种间药效和毒性物质基础不明确,有效性、安全性数据缺乏等问题。近年来,围绕多基原中药质量评价涌现出许多新思路、新模式及新方法。在整理《中国药典》2020年版收载的多基原中药概况的基础上,对多基原中药基原鉴定及质量评价新思路、新方法进行综述。为完善多基原中药质量评价体系,保障多基原中药临床用药的有效性和安全性提供支持。The quality evaluation of multi-source traditional Chinese medicine(TCM)is an important step to ensure its clinical efficacy and safety.At present,there are still some problems in the quality evaluation of multi-source TCM,such as poor specificity of the identification methods,unclear material basis of efficacy and toxic among the varieties of multi-source TCM,and lack of efficacy and safety data.In recent years,novel ideas,models and methods have emerged around the quality evaluation of multi-source TCM.Based on the profile of multi-source TCM collected in Chinese Pharmacopoeia 2020 edition,this paper expounds the novel ideas and methods of the identification and quality evaluation of multi-source TCM,it is expected to provide support to improve the quality evaluation system of multi-source TCM and ensure the efficacy and safety in clinical use.

关 键 词：多基原中药 质量评价 有效性 安全性 基原鉴定 

分 类 号：R282[医药卫生—中药学]